Nasus Pharma Announces Data Demonstrating Efficacy of TaffiX® Intranasal Antiviral Protection Against SARS-CoV-2


You May Also Like

Cellectar Biosciences to Present at NobleCon13

MADISON, Wis., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, ...

MacroGenics Highlights Progress at 2016 R&D Day

Advancement of HER2 franchise led by margetuximabExpansion and progression of B7-H3 franchiseIntroduction of PD-1 ...